Aperio Group LLC grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,078 shares of the biopharmaceutical company’s stock after purchasing an additional 4,170 shares during the quarter. Aperio Group LLC’s holdings in Alnylam Pharmaceuticals were worth $2,678,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Strs Ohio purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $141,000. CENTRAL TRUST Co boosted its stake in shares of Alnylam Pharmaceuticals by 746.3% during the fourth quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $165,000. Fayerweather Charles acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $230,000. Finally, Watch Point Trust Co acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $235,000. 88.61% of the stock is currently owned by institutional investors.
In other news, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares in the company, valued at approximately $835,859.68. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the sale, the senior vice president now owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 146,409 shares of company stock valued at $19,279,377. 4.30% of the stock is owned by insiders.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.10). The firm had revenue of $37.90 million during the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.32) EPS. equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.81 EPS for the current year.
Several brokerages have recently weighed in on ALNY. Jefferies Group set a $156.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. Leerink Swann increased their target price on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a research note on Thursday, January 25th. Cowen reiterated an “outperform” rating and set a $151.00 target price (up previously from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. B. Riley decreased their target price on shares of Alnylam Pharmaceuticals from $205.00 to $200.00 and set a “buy” rating for the company in a research note on Friday. Finally, Credit Suisse Group set a $151.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $126.76.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.